The pso Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the pso Hub cannot guarantee the accuracy of translated content. The pso and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB: For educational content and news updates.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View pso content recommended for you
CRYSTAL-Greece: Disease severity and QoL with systemic treatments in psoriasis
|
Systemic therapies are commonly used in patients with moderate-to-severe psoriasis, or in those who have not responded to topical treatment. However, there are limited real-world data on rates of complete skin clearance and disease burden in patients with psoriasis. CRYSTAL-Greece was a multicenter, single-country retrospective chart study which analyzed data from 280 Greek patients with moderate-to-severe plaque psoriasis. Enrolled patients had been on continuous treatment with a systemic therapy for ≥24 weeks. Their PASI score was evaluated at the study visit and used to confirm current disease severity. Results from the study were published by Rigopoulos et al. in the Journal of Dermatological Treatment. At diagnosis, the median patient age was 29.9 years, and baseline physician-reported psoriasis severity was mild in 38.5%, moderate in 35.2%, and severe in 26.3% of cases. |
| Key learnings |
| The median absolute PASI score was reduced from 14.7 to 1.8 from time of current systemic therapy initiation to study visit. PASI scores of ≤1, ≤3, and ≤5 were achieved by 36.8%, 64.6%, and 83.9% of patients, respectively, indicating persistent disease. |
| At the study visit, 18.9% of patients had a DLQI score >5 with 58.6% of patients reporting anxiety/depression and 28.6% experiencing pain/discomfort after treatment with systemic therapy for ≥24 weeks. |
| Absolute PASI >5 rates were 13.7% in the biologic and 28.9% in the nonbiologic monotherapy subgroups, respectively. More patients receiving biologic treatments were completely satisfied with the treatment (49.3%) compared with patients receiving nonbiologics (17.8% ). |
| Complete skin clearance remains an unmet need in many patients with psoriasis. Biologic therapies, including those targeting TNF, IL-17, and IL-12/23 pathways show promise for improving outcomes in moderate-to-severe disease. |
Abbreviations: DLQI, Dermatology Life Quality Index; IL, interleukin; PASI, Psoriasis Area and Severity Index; TNF, tumor necrosis factor.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
